Treatment of chronic hepatitis B: Evolution over two decades

Abstract excerpt

There has been a recent paradigm shift in the indications and endpoints of treatment for chronic hepatitis B (CHB). Hepatitis B e antigen (HBeAg)-negative disease is being increasingly recognized. Antiviral treatment for both HBeAg-positive and HBeAg-negative patients should aim at long-term suppression of HBV DNA, with the ultimate ideal endpoint of hepatitis B surface antigen (HBsAg) seroconversion....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis B Virus Studies
• Share to Hepatitis C virus research
• Share to Hepatitis Viruses Studies and Epidemiology